472 related articles for article (PubMed ID: 17309144)
1. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Gradiser M; Matovinovic M; Vrkljan M
Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
[TBL] [Abstract][Full Text] [Related]
2. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
3. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
4. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
5. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
6. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
7. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
8. [Pregnancy in active acromegaly].
Sahli R; Christ E
Dtsch Med Wochenschr; 2008 Nov; 133(45):2328-31. PubMed ID: 18958828
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.
Slingerland LI; Voorhout G; Rijnberk A; Kooistra HS
Domest Anim Endocrinol; 2008 Nov; 35(4):352-61. PubMed ID: 18801640
[TBL] [Abstract][Full Text] [Related]
10. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
11. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
12. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
Candrina R
Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
[TBL] [Abstract][Full Text] [Related]
13. Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess.
Kalavalapalli S; Reid H; Kane J; Buckler H; Trainer P; Heald AH
Ann Clin Biochem; 2007 Jan; 44(Pt 1):89-93. PubMed ID: 17270100
[TBL] [Abstract][Full Text] [Related]
14. Gamma knife radiosurgery for acromegaly--long-term experience.
Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L
Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
[TBL] [Abstract][Full Text] [Related]
15. A case of acromegaly in pregnancy: concomitant transsphenoidal adenomectomy and cesarean section.
Guven S; Durukan T; Berker M; Basaran A; Saygan-Karamursel B; Palaoglu S
J Matern Fetal Neonatal Med; 2006 Jan; 19(1):69-71. PubMed ID: 16492596
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin secreting pituitary adenoma accompanying a silent somatotropinoma.
Berker D; Isik S; Aydin Y; Tutuncu Y; Akdemir G; Ozcan HN; Guler S
Turk Neurosurg; 2011; 21(3):403-7. PubMed ID: 21845579
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
[TBL] [Abstract][Full Text] [Related]
18. [Acromegaly and pregnancy: report of six new cases].
Persechini ML; Gennero I; Grunenwald S; Vezzosi D; Bennet A; Caron P
J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):704-12. PubMed ID: 24035359
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of ectopic pituitary adenoma and empty sella in a patient with acromegaly : a case report and review of literature.
Hong JF; Ding XH; Wang SS
Neurol India; 2012; 60(3):304-6. PubMed ID: 22824688
[TBL] [Abstract][Full Text] [Related]
20. Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma.
Shin MS; Yu JH; Choi JH; Jung CH; Hwang JY; Cho YH; Kim CJ; Kim MS
Neurosurgery; 2013 Sep; 73(3):473-9; quiz 479. PubMed ID: 23728452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
